News about Global Pharma

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB).

Global Pharma | 26/05/2025 | By Manvi |  247

US FDA Approves Use of Nucala (Mepolizumab) to Treat COPD in Adults

The US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) from GSK plc. as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.

Global Pharma | 26/05/2025 | By Manvi |  367

InnoCare Secures China's NMPA Approval for Minjuvi Combo in Treating Relapsed DLBCL

InnoCare Pharma has received China National Medical Products Administration (NMPA) approval for Minjuvi (tafasitamab) plus lenalidomide to treat adult patients with relapsed or refractory DLBCL in China who are ineligible for stem cell transplant.

Global Pharma | 23/05/2025 | By Manvi |  430

NextCell and Fujifilm Irvine Scientific Enter Strategic Pact

The collaboration between NextCell Pharma and Fujifilm Irvine Scientific Inc. will bring together their core expertise in mesenchymal stromal cells (MSCs) and raw materials for the life science sector.

Global Pharma | 23/05/2025 | By Manvi |  246

Venus Remedies Secures Ukrainian GNP Renewal for Baddi Facility

Venus Remedies aims to strengthen its global pharmaceutical presence after the renewal of GMP certification from Ukraine's State Service on Medicines and Drugs Control (SMDC) for its Unit-II manufacturing facility located in Baddi, Himachal Pradesh.

Global Pharma | 23/05/2025 | By Manvi |  589

Malaysian Government Extends Insulin Supply Contract with Biocon Biologics

The Malaysian Health Ministry has extended the contract with Biocon Biologics to continue insulin supply under the partnership with Duopharma and Biocon Sdn. Bhd.

Global Pharma | 23/05/2025 | By Manvi |  411

Bayer Gets Regulatory Approval of Aflibercept 8 MG in China

China gives approval to Bayer over the Application for Regulatory Approval of Aflibercept 8 MG used for the treatment of neovascular (wet) age-related macular degeneration (nAMD).

Global Pharma | 23/05/2025 | By Manvi |  584

Ecolab Life Sciences Opens New Bioprocessing Applications Laboratory in US

Ecolab’s new bioprocessing applications laboratory in the US will support biopharma and CDMOs with bioprocessing applications and purification development.

Global Pharma | 23/05/2025 | By Manvi |  524

Celltrion's YUFLYMA Secures FDA Interchangeability Designation

Celltrion has announced that the FDA has granted expanded interchangeable designation to YUFLYMA (adalimumab-aaty), now covering prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations, making it fully interchangeable with Humira.

Global Pharma | 23/05/2025 | By Manvi |  340

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

Pfizer and Chinese biopharmaceutical company 3SBio have entered into a licensing agreement valued at approximately USD 6 billion for the development, manufacturing, and commercialisation of SSGJ-707, a drug candidate targeting various cancers.

Global Pharma | 22/05/2025 | By Manvi |  520